| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Product revenue | 0 | NaN | NaN | NaN |
| Product cost of sales | 0 | NaN | NaN | NaN |
| Gross income | 0 | NaN | NaN | NaN |
| Stock based compensation expenses | 104,854 | 84,636 | 377,187.5* | 13,762 |
| Research and development expenses | 873,472 | 1,545,513 | 646,282* | 707,747 |
| Administrative expenses | 894,297 | 841,685 | 975,244* | 1,104,130 |
| Series g warrant issuance expenses | 0 | NaN | 242,376.25* | NaN |
| Series f-1 warrant issuance expenses | 0 | NaN | 134,774.25* | NaN |
| Gain (losses) on fair value of derivative liability | NaN | NaN | NaN | -356,000 |
| Loss from operations | -1,872,623 | -2,471,834 | -2,375,864* | -1,825,639 |
| Changeinfairvalueofmarketablesecurities | NaN | NaN | NaN | 4,746 |
| Unrealized gain on marketable securities | NaN | NaN | 167.75* | NaN |
| Gainlossonsalesofmarketablesecurities | NaN | NaN | NaN | 551 |
| (gain)/loss on sale of marketable securities | 0 | NaN | 244* | NaN |
| Interest and dividend income | 57,575 | 62,512 | 74,160.5* | 163,951 |
| Gain on sale of investments | NaN | 2,176 | NaN | NaN |
| Casualtygainloss | NaN | NaN | NaN | 100,000 |
| Change in fair value of derivatives liabilities | 19,000 | 1,284,000 | NaN | NaN |
| Change in fair value of warrant liabilities | 0 | NaN | 1,531,983.75* | 17,000 |
| Change in fair value of derivatives liabilities | NaN | NaN | -97,000* | NaN |
| Loss on issuance of series g convertible preferred stock | 0 | NaN | 1,277,250* | NaN |
| Loss on issuance of series f-1 convertible preferred stock | 0 | NaN | 934,250* | NaN |
| Casualty loss/(gain) | NaN | NaN | 25,000* | NaN |
| Unrealized loss on marketable securities | NaN | -1,597 | NaN | NaN |
| Change in fair value of marketable securities | -147 | NaN | NaN | NaN |
| Total other (income)/expense | 76,428 | 1,347,091 | -3,740,911.5* | -103,752 |
| Loss before income tax | -1,796,195 | -1,124,743 | -6,116,775.5* | -1,929,391 |
| Income tax benefit | 0 | NaN | 0* | NaN |
| Net loss | -1,796,195 | -1,124,743 | -6,116,775.5* | -1,929,391 |
| Preferred stock dividends | 976,369 | 813,496 | 1,509,297* | 751,052 |
| Net loss attributable to common stockholders | -2,772,564 | -1,938,239 | -7,626,072.5 | -2,680,443 |
| Basic EPS | -0.18 | -0.36 | -2.91 | -1.11 |
| Diluted EPS | -0.18 | -0.36 | -2.91 | -1.11 |
| Basic Average Shares | 15,698,856 | 5,349,662 | 2,620,212 | 2,415,089 |
| Diluted Average Shares | 15,698,856 | 5,349,662 | 2,620,212 | 2,415,089 |
TNF Pharmaceuticals, Inc. (TNFA)
TNF Pharmaceuticals, Inc. (TNFA)